851785-21-2 Usage
Uses
Used in Pharmaceutical Industry:
Methyl (S)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its unique properties, including the presence of the methylsulfonyl group, make it a valuable component in the development of drugs with specific therapeutic effects.
Used in Organic Chemistry:
In the field of organic chemistry, methyl (S)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride is utilized as a chiral building block. Its versatility as a nucleophile allows it to participate in a wide range of chemical reactions, contributing to the synthesis of complex organic compounds and molecules with specific functionalities.
Used in the Development of Biologically Active Molecules:
Due to its unique structural features and reactivity, methyl (S)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride is employed in the creation of biologically active molecules. Its incorporation into these molecules can enhance their interaction with biological targets, potentially leading to the discovery of new therapeutic agents or probes for biological research.
Check Digit Verification of cas no
The CAS Registry Mumber 851785-21-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,1,7,8 and 5 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 851785-21:
(8*8)+(7*5)+(6*1)+(5*7)+(4*8)+(3*5)+(2*2)+(1*1)=192
192 % 10 = 2
So 851785-21-2 is a valid CAS Registry Number.
851785-21-2Relevant academic research and scientific papers
NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST
-
Page/Page column 16-17, (2019/05/02)
The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).
MODULATORS OF CELLULAR ADHESION
-
Page/Page column 92-93, (2010/02/11)
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
